# Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder

> **NCT00216723** · — · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 3000 (estimated)

## Conditions studied

- Schizophrenia
- Bipolar Disorder

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT00216723
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2009-12
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2013-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216723, "Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00216723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*